

CV and Financial Disclosure of Board

Name: Sebastian Wolf

Title: Prof. Dr. med. Dr.-Ing.

Main Employment

Dep. Ophthalmology, Inselspital, Bern University Hospital, University of Bern, Switzerland

Location: Bern, Switzerland

Position: Director and Chairman

Curriculum Vitae

Medical School: RWTH Aachen, Germany

Other Degrees: PhD for Biomedical engineering

Primary Fields of Interest: vitreo-retinal disease, AMD

Research Interests: AMD, Diabetic Retinopathy, Vitreo-retinal surgery, Imaging

Publications in 2017:

1. Dysli C, Wolf S, Berezin MY, et al. Fluorescence lifetime imaging ophthalmoscopy. *Prog Retin Eye Res* 2017;60:120-43.
2. Cheung CMG, Arnold JJ, Holz FG, et al. Myopic Choroidal Neovascularization: Review, Guidance, and Consensus Statement on Management. *Ophthalmology* 2017.
3. Munk MR, Giannakaki-Zimmermann H, Berger L, et al. OCT-angiography: A qualitative and quantitative comparison of 4 OCT-A devices. *PLoS One* 2017;12(5):e0177059.
4. Giannakaki-Zimmermann H, Munk MR, Dysli C, et al. Optical Coherence Tomography Angiography Features of Torpedo Maculopathy. *Retin Cases Brief Rep* 2017.
5. Munk MR, Lincke J, Giannakaki-Zimmermann H, et al. Comparison of 55 degrees Wide-Field Spectral Domain Optical Coherence Tomography and Conventional 30 degrees Optical Coherence Tomography for the Assessment of Diabetic Macular Edema. *Ophthalmologica* 2017;237(3):145-52.
6. Holz FG, Sadda SR, Staurenghi G, et al. Imaging Protocols in Clinical Studies in Advanced Age-Related Macular Degeneration: Recommendations from Classification of Atrophy Consensus Meetings. *Ophthalmology* 2017;124(4):464-78.
7. Freiberg FJ, Brynskov T, Munk MR, et al. LOW ENDOPHTHALMITIS RATES AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS IN AN OPERATION ROOM: A Retrospective Multicenter Study. *Retina* 2017.
8. Dysli C, Berger L, Wolf S, Zinkernagel MS. Fundus Autofluorescence Lifetimes and Central Serous Chorioretinopathy. *Retina* 2017.
9. Zinkernagel MS, Zysset-Burri DC, Keller I, et al. Association of the Intestinal Microbiome with the Development of Neovascular Age-Related Macular Degeneration. *Sci Rep* 2017;7:40826.
10. Ebnetter A, Waldmeier D, Zysset-Burri DC, et al. Comparison of two individualized treatment regimens with ranibizumab for diabetic macular edema. *Graefes Arch Clin Exp Ophthalmol* 2017;255(3):549-55.
11. Ceklic L, Munk MR, Wolf-Schnurrbusch U, et al. Visual Acuity Outcomes of Ranibizumab Treatment in Pathologic Myopic Eyes with Macular Retinoschisis and Choroidal Neovascularization. *Retina* 2017;37(4):687-93.

Financial Declaration for 2017

1) Payment to you directly for services you have provided (speaker fees, honoraria, consultancy, advisory board fees, investigator etc)

Company: (include all applicable companies)

Nothing to declare

2) Payment to your institution for services you have provided (speaker fees, honoraria, consultancy, advisory board fees, investigator etc)

Company: Allergan, Alcon, Bayer, Boehringer Ingelheim, Heidelberg Engineering, Novartis, Optos, Roche, Zeiss

- 3) Personal investment in a pharmaceutical or medical device company
Company: (include all applicable companies) **Nothing to declare**
- 4) Payment of royalties for intellectual property in a pharmaceutical or medical device company
Company: (include all applicable companies) **Nothing to declare**
- 5) Research funding received personally
Company: (include all applicable companies) **Nothing to declare**
- 6) Research funding received by your department or institution for research you are carrying out
Company: Allergan, Alcon, Bayer, Heidelberg Engineering, Novartis, Roche, Zeiss
- 7) Receive travel funding for meetings, full or partial
Company: Bayer, Heidelberg Engineering, Zeiss
- 8) Any other financial interests
Company: (include all applicable companies) **Nothing to declare**
Details: